Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

372 ARTÍCULOS , VIENDO DEL 76 AL 90

γ-secretase substrates and their implications for drug development in Alzheimer's disease

Lleó A, Saura CA.

Curr Top Med Chem. 2011;11(12):1513-27. doi: 10.2174/156802611795861004.

Drug discovery for neurodegenerative diseases: challenges and novel biochemical targets dedicated to the memory of Mark A. Smith for his inspiring contribution to Alzheimer's disease

Britton GB, Smith MA, Perry G, Sambamurti K, Jagannatha Rao KS.

J Alzheimers Dis. 2011;24 Suppl 2:1-2. doi: 10.3233/JAD-2011-110021.

[Do medicines with aim to anti-Alzheimer favor the arisen of epileptic crisis? Discussion about 3 clinical cases]

Roy M, Castro-Lionard K, Crawford-Achour E, Desseigne N, Beyens MN, Guy C, Imler D, Cornillon D.

Therapie. 2011 May-Jun;66(3):291-3. doi: 10.2515/therapie/2011038.

Medical foods for Alzheimer's disease

Shah RC.

Drugs Aging. 2011 Jun 1;28(6):421-8. doi: 10.2165/11587380-000000000-00000.

Aβ oligomer-induced synapse degeneration in Alzheimer's disease

Wilcox KC, Lacor PN, Pitt J, Klein WL.

Cell Mol Neurobiol. 2011 Aug;31(6):939-48. doi: 10.1007/s10571-011-9691-4. Epub 2011 May 3.

Management of suspected Alzheimer's disease patients by specialist physicians at the first visit in Spain: First Consultation Study

Martínez Lozano MD, Guzmán Quilo C; Primeras Consultas Study Group.

Expert Rev Neurother. 2011 May;11(5):657-63. doi: 10.1586/ern.11.45.

Alternative drug therapies for dementia

Howland RH.

J Psychosoc Nurs Ment Health Serv. 2011 May;49(5):17-20. doi: 10.3928/02793695-20110407-03. Epub 2011 Apr 27.

Compounding artefacts with uncertainty, and an amyloid cascade hypothesis that is 'too big to fail'

Castellani RJ, Smith MA.

J Pathol. 2011 Jun;224(2):147-52. doi: 10.1002/path.2885.

Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study

Choi SH, Park KW, Na DL, Han HJ, Kim EJ, Shim YS, Lee JH; Expect Study Group.

Curr Med Res Opin. 2011 Jul;27(7):1375-83. doi: 10.1185/03007995.2011.582484. Epub 2011 May 12.

Design and evaluation of a 6-mer amyloid-beta protein derived phage display library for molecular targeting of amyloid plaques in Alzheimer's disease: Comparison with two cyclic heptapeptides derived from a randomized phage display library

Larbanoix L, Burtea C, Ansciaux E, Laurent S, Mahieu I, Vander Elst L, Muller RN.

Peptides. 2011 Jun;32(6):1232-43. doi: 10.1016/j.peptides.2011.04.026. Epub 2011 May 6.

BACE inhibitors as potential drugs for the treatment of Alzheimer's disease: focus on bioactivity

Evin G, Lessene G, Wilkins S.

Recent Pat CNS Drug Discov. 2011 May 1;6(2):91-106. doi: 10.2174/157488911795933938.

Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies

Harrington C, Sawchak S, Chiang C, Davies J, Donovan C, Saunders AM, Irizarry M, Jeter B, Zvartau-Hind M, van Dyck CH, Gold M.

Curr Alzheimer Res. 2011 Aug;8(5):592-606. doi: 10.2174/156720511796391935.

Transgenic mice as a model for Alzheimer's disease

Lithner CU, Hedberg MM, Nordberg A.

Curr Alzheimer Res. 2011 Dec;8(8):818-31. doi: 10.2174/156720511798192736.

Anti-β-amyloid immunotherapy for Alzheimer's disease: focus on bapineuzumab

Panza F, Frisardi V, Imbimbo BP, Seripa D, Paris F, Santamato A, D'Onofrio G, Logroscino G, Pilotto A, Solfrizzi V.

Curr Alzheimer Res. 2011 Dec;8(8):808-17. doi: 10.2174/156720511798192718.

Selenium and Alzheimer's disease: a systematic review

Loef M, Schrauzer GN, Walach H.

J Alzheimers Dis. 2011;26(1):81-104. doi: 10.3233/JAD-2011-110414.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias